NASDAQ:UTHR - United Therapeutics Stock Price, News & Analysis

+0.87 (+1.09 %)
(As of 09/15/2019 04:00 PM ET)
Today's Range
Now: $80.69
50-Day Range
MA: $80.82
52-Week Range
Now: $80.69
Volume502,186 shs
Average Volume379,197 shs
Market Capitalization$3.54 billion
P/E Ratio6.03
Dividend YieldN/A
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:UTHR



Sales & Book Value

Annual Sales$1.63 billion
Cash Flow$14.4865 per share
Book Value$63.98 per share


Net Income$589.20 million


Market Cap$3.54 billion
Next Earnings Date10/30/2019 (Estimated)

Receive UTHR News and Ratings via Email

Sign-up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.

United Therapeutics (NASDAQ:UTHR) Frequently Asked Questions

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) announced its earnings results on Wednesday, July, 31st. The biotechnology company reported $4.66 EPS for the quarter, topping the consensus estimate of $2.40 by $2.26. The biotechnology company had revenue of $373.60 million for the quarter, compared to the consensus estimate of $331.78 million. United Therapeutics had a negative net margin of 7.69% and a negative return on equity of 4.54%. View United Therapeutics' Earnings History.

When is United Therapeutics' next earnings date?

United Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, October 30th 2019. View Earnings Estimates for United Therapeutics.

What price target have analysts set for UTHR?

11 brokers have issued 1-year price objectives for United Therapeutics' stock. Their forecasts range from $90.00 to $273.00. On average, they expect United Therapeutics' stock price to reach $125.30 in the next year. This suggests a possible upside of 55.3% from the stock's current price. View Analyst Price Targets for United Therapeutics.

What is the consensus analysts' recommendation for United Therapeutics?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 1 sell rating, 5 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for United Therapeutics.

What are Wall Street analysts saying about United Therapeutics stock?

Here are some recent quotes from research analysts about United Therapeutics stock:
  • 1. According to Zacks Investment Research, "United Therapeutics beat on both earnings and sales in Q2. It holds a strong position in the PAH market. Demand for its treprostinil medicines — Remodulin, Tyvaso and Orenitram — remains strong despite generic concerns and competitive pressure. It is working on new delivery mechanisms for Remodulin and expanded indications for its other marketed products like Orenitram and Tyvaso, which might drive long-term growth. Moreover, the company bought several new product candidates in 2018 to strengthen its pipeline. However, competition in the PAH market is increasing. Also, two of its biggest products — Remodulin and Adcirca —lost exclusivity in 2018. Generic versions of both the drugs have been launched, which could significantly erode the drugs’ sales in 2019. The stock has also underperformed the industry this year so far" (8/14/2019)
  • 2. HC Wainwright analysts commented, "Our price target of $95/share is based on an equally weighted composite of (a) $98/share, as a 35x multiple of taxed and diluted FY22 GAAP EPS of $5.78 discounted back to and (b) an NPV of $92/share, discount rate 12.5%, growth rate -2%." (11/1/2018)

Has United Therapeutics been receiving favorable news coverage?

Headlines about UTHR stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. United Therapeutics earned a news sentiment score of 0.9 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for United Therapeutics.

Are investors shorting United Therapeutics?

United Therapeutics saw a drop in short interest during the month of August. As of August 31st, there was short interest totalling 2,274,500 shares, a drop of 13.3% from the July 31st total of 2,623,000 shares. Based on an average trading volume of 686,500 shares, the days-to-cover ratio is presently 3.3 days. Currently, 5.4% of the company's stock are short sold. View United Therapeutics' Current Options Chain.

Who are some of United Therapeutics' key competitors?

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Celgene (CELG), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Allergan (AGN), Johnson & Johnson (JNJ), CytoDyn (CYDY), Alexion Pharmaceuticals (ALXN) and NVIDIA (NVDA).

Who are United Therapeutics' key executives?

United Therapeutics' management team includes the folowing people:
  • Dr. Martine A. Rothblatt, Founder, Chairman & CEO (Age 64)
  • Mr. Michael I. Benkowitz, Pres & COO (Age 47)
  • Mr. James C. Edgemond, CFO & Treasurer (Age 51)
  • Mr. Paul A. Mahon, Exec. VP, Gen. Counsel & Corp. Sec. (Age 55)
  • Kevin T. Gray, Sr. VP of Strategic Operations & Logistics

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.25%), BlackRock Inc. (10.25%), Vanguard Group Inc. (9.10%), Renaissance Technologies LLC (6.93%), First Trust Advisors LP (2.76%) and AQR Capital Management LLC (2.58%). Company insiders that own United Therapeutics stock include Christopher Causey, Christopher Patusky, Judy D Olian, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Institutional Ownership Trends for United Therapeutics.

Which institutional investors are selling United Therapeutics stock?

UTHR stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, APG Asset Management N.V., BlackRock Inc., BlackRock Inc., Robeco Institutional Asset Management B.V., LSV Asset Management, Invesco Ltd. and Skandinaviska Enskilda Banken AB publ. Company insiders that have sold United Therapeutics company stock in the last year include Christopher Patusky, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Insider Buying and Selling for United Therapeutics.

Which institutional investors are buying United Therapeutics stock?

UTHR stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Point72 Asset Management L.P., Camber Capital Management LP, Nuveen Asset Management LLC, Brandes Investment Partners LP, Pictet Asset Management Ltd., Pictet Asset Management Ltd. and Cubist Systematic Strategies LLC. View Insider Buying and Selling for United Therapeutics.

How do I buy shares of United Therapeutics?

Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is United Therapeutics' stock price today?

One share of UTHR stock can currently be purchased for approximately $80.69.

How big of a company is United Therapeutics?

United Therapeutics has a market capitalization of $3.54 billion and generates $1.63 billion in revenue each year. The biotechnology company earns $589.20 million in net income (profit) each year or $13.39 on an earnings per share basis. United Therapeutics employs 860 workers across the globe.View Additional Information About United Therapeutics.

What is United Therapeutics' official website?

The official website for United Therapeutics is

How can I contact United Therapeutics?

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at 301-608-9292 or via email at [email protected]

MarketBeat Community Rating for United Therapeutics (NASDAQ UTHR)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  428 (Vote Outperform)
Underperform Votes:  577 (Vote Underperform)
Total Votes:  1,005
MarketBeat's community ratings are surveys of what our community members think about United Therapeutics and other stocks. Vote "Outperform" if you believe UTHR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UTHR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/15/2019 by Staff

Featured Article: What is a support level?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel